HS PROGRESS is designed to facilitate hidradenitis suppurativa (HS) research through collaboration between investigators, clinicians, patients and industry in order accelerate the development of therapies to improve the lives of people living with this skin painful condition.
The microbiome is a vast community that changes how we digest food, how we respond to disease threats, and even how we think. But scientists are just scratching the surface of how our microscopic roommates affect our health.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) continued to make strides against cancer in 2024. Laboratory research teams across the institution worked to advance the global understanding of cancer and to develop new therapies, while also making fundamental insights into human biology and disease.
After dozens of clinical trials, there are still no effective vaccines against Staphylococcus aureus. In two new studies, scientists report that the pathogen turns on the protein interleukin 10, shutting down the protective vaccine response. But blocking the protein restores vaccine efficacy in an animal model.
A team led by Michel Desjardins, a professor in the Faculty of Medicine, has secured $8M from ASAP to study the connection between the immune system and Parkinson's disease.
Bacteria face multiple stressors in the human body, including fluid flow. A new University of Illinois study found that combining the stress of fluid flow with the chemical stress of the hydrogen peroxide naturally present in the body synergizes to block bacterial migration and growth of the human pathogen Pseudomonas aeruginosa.
If you have allergies or asthma, keeping yourself healthy and free of symptoms needs to be a priority, doesn’t have to be complicated.
Researchers discovered a vulnerability in viral enzymes that could lead to novel treatments for diseases as diverse as COVID and Ebola, while also minimizing side effects and reducing the odds of drug resistance.
As a second wave of the viral disease looms, Rutgers Health researchers call for more studies on long-term immunity.
In his expanded health system role, Ralph Weichselbaum leads efforts to bring radiation therapy to patients at the University of Chicago Medicine, including in Chicago’s suburbs and in Northwest Indiana.
Charles “Chuck” Shoemaker, a professor in the Department of Infectious Disease and Global Health at Cummings School of Veterinary Medicine at Tufts University, has been named a fellow of the National Academy of Inventors (NAI). Election as an academy fellow is the highest professional distinction awarded solely to inventors.
A study sheds new light on how Toxoplasma gondii parasites make the proteins they need to enter a dormant stage that allows them to escape drug treatment.
Sapna Chitlapilly Dass, Ph.D., assistant professor in microbial ecology and microbiome interactions, Department of Animal Science, is studying the ongoing threat of emerging pathogens that can necessitate prompt deployment of medical countermeasures for life-saving interventions.
Researchers from the University of Illinois have reported complementary discoveries that improve scientists’ understanding of immune systems in bacteria and will equip clinicians with more effective options for treating antibiotic-resistant infections.
Researchers found that transmission of rotavirus vaccine strains in a neonatal intensive care unit (NICU) is rare and without clinical consequences, strongly suggesting that giving the rotavirus vaccine to eligible infants during their hospitalization provides immune benefits that outweigh any risks. The findings could serve as the basis for a change in clinical practice.
A preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates — FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Research out of Roswell Park Comprehensive Cancer Center has shed light on how the drug venetoclax (brand name Venclexta) works synergistically with CAR T-cell immunotherapy to combat chronic lymphocytic leukemia (CLL), the most common type of leukemia in the U.S. Matthew Cortese, MD, MPH, Assistant Professor of Oncology in Roswell Park’s departments of Medicine and Cancer Genetics & Genomics, is first author of the study, which he will present during an oral abstract session today at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
